Hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: Should we be targeting sarcopenia induced brain dysfunction?
Background: The United States Centers for Disease Control and Prevention (CDC) esti-mates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmaco-logical treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval: This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of pre-cursor amino acid therapy and modulation of enkephalinase, MOA, and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhance-ment via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce an-giogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to over-come this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention.
Blum, Kenneth; Gold, Mark S.; Llanos-Gomez, Luis; Jalali, Rehan; Thanos, Panayotis K.; Bowirrat, Abdalla; Downs, William B.; Bagchi, Debasis; Braverman, Eric R.; Baron, David; Roy, Alphonso Kenison; and Badgaiyan, Rajendra D., "Hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: Should we be targeting sarcopenia induced brain dysfunction?" (2021). Faculty Publications. 8.